- Conditions
- Refractory Solid Tumors
- Interventions
- Eribulin, Irinotecan, Temozolomide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 115
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Paclitaxel, Eribulin, 5-Fluorouracil, Epirubicin, Cyclophosphamide, Doxorubicin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
- Interventions
- SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
- Biological · Drug
- Lead sponsor
- BriaCell Therapeutics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 79
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more
- Conditions
- Solid Tumor
- Interventions
- Eribulin ORA
- Combination Product
- Lead sponsor
- Health Hope Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Pediatrics, Solid Tumors
- Interventions
- Eribulin Mesylate
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 15 more
- Conditions
- Breast Cancer, Breast Neoplasms
- Interventions
- Taxane, Vinorelbine, Ixabepilone, Eribulin, Chemotherapy
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Breast Cancer
- Interventions
- Eribulin Mesylate, Ixabepilone
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 50
- States / cities
- Sedona, Arizona • Hawthorne, California • Los Angeles, California + 39 more
- Conditions
- Breast Cancer, Metastatic Triple-Negative Breast Cancer
- Interventions
- Eribulin, SDX-7320, Placebo
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 10
- States / cities
- Miami, Florida • Atlanta, Georgia • Basking Ridge, New Jersey + 7 more
- Conditions
- Metastatic HER2-positive Breast Cancer
- Interventions
- Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Cerritos, California + 34 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- E7389
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 9
- States / cities
- Duarte, California • Miami, Florida • Atlanta, Georgia + 6 more
- Conditions
- Metastasis, Breast Cancer
- Interventions
- NKTR-102, Eribulin, Ixabepilone, Vinorelbine, Gemcitabine, Paclitaxel, Docetaxel, Nab-paclitaxel
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Orange, California • San Francisco, California + 16 more
- Conditions
- HER2-normal
- Interventions
- eribulin mesylate
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • New York, New York
- Conditions
- Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
- Interventions
- Tucatinib, Eribulin, Trastuzumab
- Drug
- Lead sponsor
- Criterium, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Albuquerque, New Mexico + 3 more
- Conditions
- Liposarcoma, Malignant Abdominal Neoplasm, Malignant Retroperitoneal Neoplasm, Malignant Scrotal Neoplasm, Malignant Solid Neoplasm, Malignant Spermatic Cord Neoplasm
- Interventions
- Eribulin Mesylate, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery
- Drug · Radiation · Other + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2033
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Breast Cancer
- Interventions
- Ramucirumab (IMC-1121B), Eribulin
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Gilroy, California • Palm Springs, California + 49 more
- Conditions
- Breast Cancer
- Interventions
- Eribulin Mesylate
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 12
- States / cities
- Denver, Colorado • Columbia, Maryland • Omaha, Nebraska + 8 more
- Conditions
- Breast Cancer
- Interventions
- E7389
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 48 more
- Conditions
- Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Interventions
- Eribulin, Adriamycin, Cyclophosphamide
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Breast Cancer
- Interventions
- Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Selicrelumab, Tocilizumab, Nab-Paclitaxel, Sacituzumab Govitecan, Abemaciclib, Fulvestrant, Ribociclib (Dose #1), Inavolisib (Dose #1), Trastuzumab Deruxtecan, Ribociclib (Dose #2), Letrozole, Inavolisib (Dose #2), Empagliflozin, Palbociclib, Metformin, Atirmociclib, Giredestrant
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 24
- States / cities
- Duarte, California • Irvine, California • La Jolla, California + 18 more
- Conditions
- Breast Cancer
- Interventions
- AEZS-108, SCCC, Dexamethasone
- Drug
- Lead sponsor
- AEterna Zentaris
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Metastatic Breast Cancer
- Interventions
- POL6326
- Drug
- Lead sponsor
- Polyphor Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 5
- States / cities
- Kansas City, Kansas • St Louis, Missouri • Lebanon, New Hampshire + 2 more
- Conditions
- Locally Recurrent, Metastatic Breast Cancer ( HER2 Negative)
- Interventions
- Eribulin mesylate
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 17
- States / cities
- Miami, Florida • Augusta, Georgia • Macon, Georgia + 13 more
- Conditions
- HER-2 Positive Breast Cancer
- Interventions
- eribulin, carboplatin, trastuzumab
- Drug
- Lead sponsor
- Vector Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- Fort Lauderdale, Florida • Athens, Georgia • Marietta, Georgia + 1 more
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
- Interventions
- 75 approved agents, COXEN
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland